Nature published a long-read on June 8 reviewing the consumer peptide boom against the actual evidence base. Worldwide Google searches for 'peptides' rose from about 1.3 million per month in 2024 to around 8 million in 2026, fueled by social media. Most popularly promoted compounds (BPC-157, TB-500, GHK-Cu, CJC-1295) rest on animal data, with one human study described as showing 'significant methodological problems and no control group.' The piece lands two months before the July 23-24 PCAC meeting that will rule on whether seven of these peptides can return to legal 503A compounding.
A STAT and Undark investigation, supported by the Pulitzer Center and widely republished around June 1-2, examined the thin evidence behind BPC-157, the wound-healing peptide on the FDA's July 23-24 PCAC docket. Nearly all of the roughly 200 BPC-157 studies indexed on PubMed list Croatian researcher Predrag Sikiric or colleague Sven Seiwerth as an author, a concentration a Polish review team flagged as a confirmation-bias risk, and Sikiric's undisclosed conflicts include patents dating to 1989 and a CEO role at Diagen, which sells a patented version. Only three human studies have been published; STAT ran a June 1 follow-up carrying Sikiric's response to skeptics.
Comprehensive look at peptide therapies from approved GLP-1s to unregulated substances like BPC-157 and TB-500. Most evidence comes from animal studies, with benefits "largely unvalidated in human trials."
Eric Topol of Scripps Research called peptide data "woefully minuscule," warning about impurities, random dosing, and dangerous stacking of unproven compounds from gray-market sources.